Compare Stocks → The asset beating inflation by 4x (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ACRNYSEARCA:BNOCVE:MPHNASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRACRES Commercial Realty$13.65+5.0%$12.83$6.62▼$14.35$104.70M1.9917,510 shs7,906 shsBNOUnited States Brent Oil Fund$30.83-0.9%$31.60$24.02▼$33.91$127.94M0.2594,579 shs599,074 shsMPHMedicureC$1.07+7.0%C$1.10C$0.99▼C$1.80C$10.97M1.014,451 shs3,000 shsRZLTRezolute$3.31+11.4%$2.32$0.72▼$3.69$132.83M1.29314,874 shs335,692 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRACRES Commercial Realty+5.00%-1.16%-3.40%+34.88%+64.06%BNOUnited States Brent Oil Fund-0.87%-5.78%-6.18%+11.34%+27.66%MPHMedicure0.00%+7.00%+0.94%-14.40%-14.40%RZLTRezolute+11.45%+24.44%+39.08%+215.24%+53.95%FW: 234x Gain (Ad)This coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRACRES Commercial Realty2.5406 of 5 stars2.53.00.00.01.70.83.1BNOUnited States Brent Oil FundN/AN/AN/AN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/ARZLTRezolute3.2951 of 5 stars3.54.00.00.03.14.20.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRACRES Commercial Realty3.00Buy$15.5013.55% UpsideBNOUnited States Brent Oil Fund0.00N/AN/AN/AMPHMedicureN/AN/AN/AN/ARZLTRezolute3.00Buy$8.80165.86% UpsideCurrent Analyst RatingsLatest ACR, MPH, BNO, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2024ACRACRES Commercial RealtyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$14.00 ➝ $15.504/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/14/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRACRES Commercial Realty$91.13M1.15$5.71 per share2.39$52.77 per share0.26BNOUnited States Brent Oil FundN/AN/AN/AN/AN/AN/AMPHMedicureC$22.94M0.48C$0.43 per share2.49C$2.10 per share0.51RZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRACRES Commercial Realty$22.39M$0.7019.506.53N/A28.51%7.75%1.54%8/7/2024 (Estimated)BNOUnited States Brent Oil FundN/AN/A0.00∞N/AN/AN/AN/AN/AMPHMedicureC$1.08MC$0.0911.89∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)RZLTRezolute-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)Latest ACR, MPH, BNO, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024Q1 2024ACRACRES Commercial Realty$0.35$0.10-$0.25$0.13$13.00 million$18.77 million 4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million2/13/2024Q2 2024RZLTRezolute-$0.27-$0.27N/A-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRACRES Commercial RealtyN/AN/AN/AN/AN/ABNOUnited States Brent Oil FundN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRACRES Commercial Realty3.7684.0184.01BNOUnited States Brent Oil FundN/AN/AN/AMPHMedicure2.862.281.29RZLTRezoluteN/A12.0012.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRACRES Commercial Realty40.03%BNOUnited States Brent Oil FundN/AMPHMedicure23.10%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipACRACRES Commercial Realty3.60%BNOUnited States Brent Oil FundN/AMPHMedicure26.99%RZLTRezolute18.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRACRES Commercial Realty2,0187.67 million7.40 millionOptionableBNOUnited States Brent Oil FundN/A4.15 millionN/ANot OptionableMPHMedicureN/A10.25 millionN/ANot OptionableRZLTRezolute5740.13 million32.83 millionNot OptionableACR, MPH, BNO, and RZLT HeadlinesSourceHeadlineVivo Capital LLC Has $7.13 Million Position in Rezolute, Inc. (NASDAQ:RZLT)marketbeat.com - April 27 at 9:40 PMFederated Hermes Inc. Purchases 3,544,053 Shares of Rezolute, Inc. (NASDAQ:RZLT)marketbeat.com - April 24 at 5:43 AMPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meetingglobenewswire.com - April 23 at 8:00 AMJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendationmsn.com - April 19 at 8:15 AMRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMJonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)marketbeat.com - April 18 at 8:35 AMOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospectsmarkets.businessinsider.com - April 18 at 5:30 AMCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?investorplace.com - April 15 at 3:43 PMRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 10 at 4:10 PMRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Groupmarketbeat.com - April 9 at 8:23 AMInsiders Are Buying These 5 Penny Stocksinsidermonkey.com - April 4 at 8:51 AMRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buyingfinance.yahoo.com - March 27 at 8:51 AM3 Stocks Insiders Are Buying That Analysts Love (RZLT)insidertrades.com - March 26 at 12:55 PMRezolute's chief medical officer buys $18.8k in company stockinvesting.com - March 20 at 5:29 PMDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 20 at 7:32 AMBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stockinsidertrades.com - March 19 at 5:40 AMInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stockinsidertrades.com - March 15 at 11:42 AMRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stockinsidertrades.com - March 11 at 7:22 AMRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)globenewswire.com - March 6 at 7:30 AMRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Callsbenzinga.com - February 22 at 12:13 PMRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinanznachrichten.de - February 16 at 9:03 AMWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Ratefinance.yahoo.com - February 15 at 7:59 AMRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Updatefinance.yahoo.com - February 13 at 7:04 PMBuy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic Efficacymarkets.businessinsider.com - February 8 at 8:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesMicrosoft Fires a Trend Following Signal: Targets Move HigherApril 26, 2024 8:40 AMView Microsoft Fires a Trend Following Signal: Targets Move HigherAll Headlines Company DescriptionsACRES Commercial RealtyNYSE:ACRACRES Commercial Realty Corp., a real estate investment trust (REIT), focuses on the origination, holding, and management of commercial real estate mortgage loans and equity investments in commercial real estate property in the United States. It invests in commercial real estate-related assets, including floating-rate first mortgage loans, first priority interests in first mortgage loans, subordinated interests in first mortgage loans, mezzanine financing, preferred equity investments, and commercial mortgage-backed securities. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Exantas Capital Corp. and changed its name to ACRES Commercial Realty Corp. in February 2021. ACRES Commercial Realty Corp. was incorporated in 2005 and is based in Uniondale, New York.United States Brent Oil FundNYSEARCA:BNOThe United States Brent Oil Fund, LP (BNO) is an exchange-traded fund that is based on the Front Month Brent Crude Oil index. The fund tracks the Brent oil spot price using near-month ICE futures contracts. BNO was launched on Jun 2, 2010 and is managed by US Commodity Funds.MedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.